Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00501696 · ClinicalTrials.gov registry record · Phase 3
A Randomized Placebo-Controlled, Crossover-Design Study of the Effects of Low Dose Naltrexone
A Phase 3 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 3
- Development phase
- 80
- Enrollment target
NCT00501696 is a Phase 3 study that has completed, run by University of California, San Francisco. The registered enrollment target is 80 participants.
The verdict
NCT00501696, a Phase 3 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 80 participants
- Enrollment target
Study Summary
This is a randomized placebo-controlled, parallel-group study, crossover-design of the effects of low dose naltrexone on the multiple sclerosis quality of life inventory (MSQLI54) This study will assess the impact of LDN compared to placebo on quality of life as measured by the composite score of the MSQOL54 in adult subjects with MS. Also we plan: 1. To compare the 10 scales of the MSQOL54 during the active treatment and placebo cycles between active treatment and placebo groups 2. To compare each individual's composite response to LDN versus placebo during the active treatment and placebo cycles 3. To compare each individual on the 10 scales of the MSQOL54 during the active treatment and placebo cycles
Interventions
- DRUG Naltrexone
- DRUG 4.5 mg Naltrexone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2007-02 |
| Est. Completion | 2007-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00501696
The ClinicalTrials.gov registry entry for NCT00501696 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Naltrexone is the first listed.
NCT00501696 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00501696 about?
NCT00501696 is a clinical study titled "A Randomized Placebo-Controlled, Crossover-Design Study of the Effects of Low Dose Naltrexone". This is a randomized placebo-controlled, parallel-group study, crossover-design of the effects of low dose naltrexone on the multiple sclerosis quality of life inventory (MSQLI54) This study will assess the impact of LDN compared to placebo on quality of life as measured by the composite score of t...
What is the current status of trial NCT00501696?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 80 participants. The study started on 2007-02. Estimated completion is 2007-11.
What interventions are being tested in trial NCT00501696?
The interventions under investigation include: Naltrexone (DRUG), 4.5 mg Naltrexone (DRUG).
Who is sponsoring clinical trial NCT00501696?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.